Literature DB >> 18845259

Periplasmic cold expression and one-step purification of human dihydrolipoamide dehydrogenase.

Attila Ambrus1, Beata Torocsik, Vera Adam-Vizi.   

Abstract

Dihydrolipoamide dehydrogenase (LADH) is a FAD-linked subunit of alpha-ketoglutarate, pyruvate and branched-chain amino acid dehydrogenases and the glycine cleavage system. As an oxidoreductase it transfers electrons from the dihydrolipoic acid prosthetic group to the NAD(+) cofactor via its FAD center. Besides its physiological function it is capable of generating harmful reactive oxygen species (ROS) in pathological settings therefore it is implicated in neurodegeneration, ischemia-reperfusion, cancer and several other disorders. Pathological mutants of the enzyme cause severe, sometimes lethal syndromes like hypotonia, metabolic acidosis or inefficiency in development. Recently it has been revealed that LADH is a moonlighting protease when specific mutations in the dimerization surface destabilize the functional homodimer and expose a serine-protease-like catalytic dyad. As the basis of versatile functions of LADH is far from elucidation, there is a constant need for a pure and functional enzyme product for investigations. Several studies used recombinant human LADH before, however, it was generated by more complicated and/or physiologically less compatible protocols than reported here; most papers on functional and structural studies do not even report detailed protocols and characteristics (most importantly the purity) of their protein products. Here we describe the details of an optimized, easy-to-use periplasmic expression and one-step purification protocol for obtaining a highly pure, active and authentic (tag-cleaved) enzyme with the characterization of the protein product. The purified LADH can be used in biophysical and structural studies while the published protocol is easily convertible to a protein labeling procedure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845259     DOI: 10.1016/j.pep.2008.09.009

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  5 in total

1.  Underlying molecular alterations in human dihydrolipoamide dehydrogenase deficiency revealed by structural analyses of disease-causing enzyme variants.

Authors:  Eszter Szabo; Piotr Wilk; Balint Nagy; Zsofia Zambo; David Bui; Andrzej Weichsel; Palaniappa Arjunan; Beata Torocsik; Agnes Hubert; William Furey; William R Montfort; Frank Jordan; Manfred S Weiss; Vera Adam-Vizi; Attila Ambrus
Journal:  Hum Mol Genet       Date:  2019-10-15       Impact factor: 6.150

2.  Structural alterations induced by ten disease-causing mutations of human dihydrolipoamide dehydrogenase analyzed by hydrogen/deuterium-exchange mass spectrometry: Implications for the structural basis of E3 deficiency.

Authors:  Attila Ambrus; Junjie Wang; Reka Mizsei; Zsofia Zambo; Beata Torocsik; Frank Jordan; Vera Adam-Vizi
Journal:  Biochim Biophys Acta       Date:  2016-08-18

3.  Formation of reactive oxygen species by human and bacterial pyruvate and 2-oxoglutarate dehydrogenase multienzyme complexes reconstituted from recombinant components.

Authors:  Attila Ambrus; Natalia S Nemeria; Beata Torocsik; Laszlo Tretter; Mattias Nilsson; Frank Jordan; Vera Adam-Vizi
Journal:  Free Radic Biol Med       Date:  2015-10-09       Impact factor: 7.376

Review 4.  An Updated View on the Molecular Pathomechanisms of Human Dihydrolipoamide Dehydrogenase Deficiency in Light of Novel Crystallographic Evidence.

Authors:  Attila Ambrus
Journal:  Neurochem Res       Date:  2019-03-07       Impact factor: 3.996

5.  Periplasmic Expression of a Novel Human Bone Morphogenetic Protein-7 Mutant in Escherichia coli.

Authors:  Leila Nematollahi; Vahid Khalaj; Seyedeh Maliheh Babazadeh; Azam Rahimpour; Hoda Jahandar; Fatemeh Davami; Fereidoun Mahboudi
Journal:  Avicenna J Med Biotechnol       Date:  2012-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.